Yuandong Biotech announced that the company is developing EP-0226 tablets to treat neuropathic pain. It is a novel calcium channel modulator. Phase I clinical trials have now been completed and statistical analysis results have been obtained. The complete clinical trial report and some exploratory analyses are still being improved, and preliminary preparations for the phase II clinical trial are being stepped up. The drug has a long development cycle, large investment, and high risk, and there is uncertainty about the results of subsequent clinical trials, whether the marketing application will be approved, and when.

Yuandong Biotech announced that the company is developing EP-0226 tablets to treat neuropathic pain. It is a novel calcium channel modulator. Phase I clinical trials have now been completed and statistical analysis results have been obtained. The complete clinical trial report and some exploratory analyses are still being improved, and preliminary preparations for the phase II clinical trial are being stepped up. The drug has a long development cycle, large investment, and high risk, and there is uncertainty about the results of subsequent clinical trials, whether the marketing application will be approved, and when.